GET DAILY SIGNALSLifecore Biomedical (LFCR) Q3 2026 Earnings: Revenue Down -18.6% While Adjusted EBITDA Improves
Key Takeaways
- Lifecore Biomedical reported total revenue of $25.3 million for its third quarter of 2026, down 18.6% from $31.1 million a year earlier and slightly below the consensus estimate of roughly $25.6 million.
- The company posted a GAAP net loss of $40.1 million, or $1.08 per diluted share, versus a $10.0 million loss ($0.29 per share) in the prior-year quarter, missing consensus expectations of about a $0.30 per-share loss.
- The wider loss was driven largely by a non-cash increase in the fair value of a debt derivative liability, rather than an operational deterioration.
- Adjusted EBITDA rose to $4.0 million from $3.1 million a year earlier, reflecting ongoing cost discipline and efficiency initiatives.
- Nine-month revenue totaled $82.7 million, down 21.8% year over year, while management highlighted multiple new business wins strengthening its commercial and development pipeline.
Why These Results Matter
LFCR operates as a fully integrated CDMO focused on sterile injectable products and premium hyaluronic acid. The quarterly update is significant because the company continues its turnaround, building capacity while converting a growing development pipeline into commercial revenue. This report helps clarify whether cost controls and new program wins can offset the top-line pressure from a prior customer loss and HA inventory normalization. For investors, the gap between a wider GAAP loss and stronger adjusted EBITDA serves as an important indicator of how much of the headline loss stems from non-cash items rather than core operations.
Breaking Down the Reported Numbers
For the third quarter ended September 30, 2026, LFCR posted total revenue of $25.3 million, an 18.6% decline from $31.1 million in the same period last year. The result came in just below the consensus estimate of about $25.6 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The GAAP net loss expanded to $40.1 million, or $1.08 per diluted share, from a $10.0 million loss ($0.29 per share) a year earlier. This missed analyst expectations of roughly a $0.30 per-share loss. Management noted that much of the increase came from a non-cash charge tied to the change in fair value of a debt derivative liability, which is excluded from adjusted figures.
On an adjusted basis, adjusted EBITDA rose to $4.0 million from $3.1 million in the prior-year quarter. Gross profit fell to $6.8 million from $7.8 million, with gross margin narrowing as well. Over the first nine months of 2026, revenue reached $82.7 million (down 21.8%), while adjusted EBITDA was $13.6 million compared with $21.1 million a year ago. The company finished the quarter with roughly $38.0 million in total liquidity, including $23.0 million in cash and $15.0 million available under its revolving credit facility.
Market Reaction and Sentiment
Heading into the report, investor sentiment reflected caution around the top-line decline linked to customer concentration and HA inventory normalization. The third-quarter results did not fully ease those concerns, as revenue came in modestly below expectations and the GAAP loss widened more than anticipated due to the non-cash derivative charge.
That said, the rise in adjusted EBITDA and management’s comments on new business wins offered a more positive underlying story. The contrast between the reported GAAP loss and the improved adjusted metric highlights the need to look beyond non-cash items when assessing operating trends. Ongoing questions around customer concentration, liquidity, and the pace of pipeline conversion continue to shape how the market views these results.
Forward Outlook and Items to Watch
After the third-quarter release, several factors stand out for investors. The top priority is whether LFCR can meet its full-year 2026 guidance of roughly $120 million to $125 million in revenue and $20.5 million to $25 million in adjusted EBITDA. Achieving those targets will depend on a significant revenue increase in the fourth quarter, in line with prior indications that orders are back-half weighted.
Pipeline conversion remains another key focus. The company has cited multiple new program wins, including commercial site transfers and late-stage development opportunities. The speed at which these programs shift to commercial manufacturing will influence the ability to restore revenue growth and improve capacity utilization.
Cost and liquidity trends also warrant attention. Management has been cutting selling, general, and administrative expenses while advancing efficiency projects, and the company has begun paying a portion of debt service in cash rather than in-kind. Continued progress on free cash flow and working capital will matter given the capital structure.
Over the longer term, the company’s goals of a 12% revenue CAGR and adjusted EBITDA margins above 25% by the end of 2029 provide a benchmark for evaluating whether the current restructuring supports sustainable, profitable growth.
Refining Analysis with Tickeron Tools
From what I see, tools like Tickeron’s AI Screener can add useful context when evaluating results like these by highlighting comparable companies and technical signals. I find it helpful for quickly scanning industry peers and spotting potential patterns that might otherwise require manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFCR sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for LFCR moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFCR advanced for three days, in 210 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for LFCR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 56 cases where LFCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFCR as a result. In 70 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for LFCR turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
LFCR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LFCR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LFCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-7.061) is normal, around the industry mean (7.254). P/E Ratio (-5.008) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (2.661) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.222) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Can I Establish a SEP IRA?
What is IRS Publication 544 on Sales and Other Dispositions of Assets?
What is IRS Publication 524, Credit for the Elderly and the Disabled?
What is the Symmetrical Triangle Bottom (Bullish) Pattern?
What Is the EUR/USD Currency Pair, and How Can It Shape Your Forex Strategy?
General Information
a manufacturer of polymer products for food and agricultural products, medical devices and licensed partner applications
Industry PharmaceuticalsGeneric
Advertisement